China's CANbridge Partners with Amoy on Diagnostic For Brain Cancer Drug

Beijing's CANbridge Life Sciences partnered with Amoy Diagnostics of Xiamen, China to develop a companion diagnostic assay for CANbridge’s lead candidate, a treatment for glioblastoma multiforme. In European trials, CAN008 provided a significant overall survival benefit for recurrent GBM patients with high expression of the CD95 ligand, or low methylation of a CD95L promotor, CpG2. CAN008  is currently being tested in Phase I/II clinical study among GBM patients in Taiwan. CANbridge plans to start a China Phase II trial of CAN008 next year. More details.... Share this with colleagues: // //